Table 6.6g
Immunosuppression Use for Maintenance Between Discharge and One Year Following Transplantation, 1995 to 2004
Recipients with Pancreas Transplant Alone (PTA) Transplants

	Year of Transplant									
	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Transplants	42	52	79	89	139	134	167	180	158	183
Tx with Follow-up Immunosuppression Info	23	31	46	64	108	96	122	142	115	138
Corticosteroids										
Any in Category	87.0%	96.8%	100.0%	100.0%	100.0%	96.9%	92.6%	86.6%	56.5%	56.5%
Steroids	87.0%	96.8%	100.0%	100.0%	100.0%	96.9%	92.6%	86.6%	56.5%	56.5%
Cyclosporine										
Any in Category	43.5%	41.9%	23.9%	18.8%	8.3%	8.3%	5.7%	8.5%	7.0%	3.6%
Cyclosporin	17.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Sandimmmune	8.7%	9.7%	2.2%	0.0%	0.0%	2.1%	0.0%	0.0%	0.0%	0.0%
Neoral	17.4%	32.3%	21.7%	18.8%	8.3%	5.2%	5.7%	6.3%	6.1%	3.6%
Gengraf	0.0%	0.0%	0.0%	0.0%	0.0%	1.0%	0.0%	1.4%	0.9%	0.0%
Eon	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.0%
Tacrolimus										
Any in Category	56.5%	80.6%	80.4%	96.9%	96.3%	95.8%	98.4%	95.1%	84.3%	85.5%
Tacrolimus	56.5%	80.6%	80.4%	96.9%	96.3%	95.8%	98.4%	95.1%	84.3%	85.5%
Antimetabolites										
Any in Category	95.7%	93.5%	91.3%	93.8%	93.5%	81.3%	73.8%	64.1%	60.0%	59.4%
Mycophenolate Mofetil	43.5%	80.6%	78.3%	81.3%	91.7%	76.0%	70.5%	64.1%	59.1%	53.6%
Mycophenolate Sodium	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Azathioprine	52.2%	12.9%	13.0%	12.5%	1.9%	5.2%	3.3%	0.0%	0.9%	5.8%
Cytoxan	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
mTOR Inhibitors										
Any in Category	0.0%	0.0%	0.0%	0.0%	17.6%	27.1%	16.4%	33.1%	24.3%	26.8%
Sirolimus	0.0%	0.0%	0.0%	0.0%	17.6%	27.1%	16.4%	33.1%	24.3%	26.8%
Everolimus	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation.
Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.